Mark J. de Lange

626 citations

14 papers · 476 indexed · h-index 9

Physical Therapy, Sports Therapy and Rehabilitation top 5%
Ophthalmology top 2%
- Ocular Oncology and Treatments 8
Psychiatry and Mental health top 10%
Immunology
- Immunotherapy and Immune Responses 3
- interferon and immune responses 1
Neurology
Molecular Biology
- Retinal Development and Disorders 4
- Melanoma and MAPK Pathways 3
Cell Biology
- melanin and skin pigmentation 2
Oncology
- Cutaneous Melanoma Detection and Management 2
Biochemistry
- Phytochemicals and Antioxidant Activities 1

Co-authors: Leland E. Dibble Pieter A. van der Velden Martine J. Jager Mieke Versluis Jinfeng Cao Wilma G. M. Kroes Sjoerd H. van der Burg Claudia Ruivenkamp
Cited by: Physical Therapy, Sports Therapy and Rehabilitation Ophthalmology Psychiatry and Mental health
Journals: PLoS ONE (2 papers)Medicine (1 paper)Oncotarget (2 papers)
Partner nations: Netherlands United States China

In The Last Decade

Mark J. de Lange

14 papers receiving 466 citations

Peers

Countries citing papers authored by Mark J. de Lange

Since Specialization

Citations

This map shows the geographic impact of Mark J. de Lange's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark J. de Lange with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark J. de Lange more than expected).

Fields of papers citing papers by Mark J. de Lange

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark J. de Lange. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark J. de Lange. The network helps show where Mark J. de Lange may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Mark J. de Lange, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark J. de Lange Line = papers co-authored together Mark J. de Lange links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work
1	Scientific and clinical implications of genetic and cellular heterogeneity in uveal melanoma Molecular Biomedicine ·Mark J. de Lange,Rogier J. Nell,Pieter A. van der Velden	2021	6
2	Digital PCR-Based T-cell Quantification–Assisted Deconvolution of the Microenvironment Reveals that Activated Macrophages Drive Tumor Inflammation in Uveal Melanoma Molecular Cancer Research ·Mark J. de Lange,Rogier J. Nell,Rajshri N. Lalai,Mieke Versluis,Ekaterina S. Jordanova,Gré P.M. Luyten,Martine J. Jager,Sjoerd H. van der Burg,Willem H. Zoutman,Thorbald van Hall,Pieter A. van der Velden	2018	33
3	Loss of MAPK Pathway Activation in Post-Mitotic Retinal Cells as Mechanism in MEK Inhibition-Related Retinopathy in Cancer Patients Medicine ·Elon H. C. van Dijk,Danique E. M. Duits,Mieke Versluis,Gregrorius P. M. Luyten,Arthur A. Bergen,Ellen Kapiteijn,Mark J. de Lange,Camiel J. F. Boon,Pieter A. van der Velden	2016	34
4	Accurate Quantification of T Cells by Measuring Loss of Germline T-Cell Receptor Loci with Generic Single Duplex Droplet Digital PCR Assays Journal of Molecular Diagnostics ·Willem H. Zoutman,Rogier J. Nell,Mieke Versluis,Debby van Steenderen,Rajshri N. Lalai,Jacoba J. Out‐Luiting,Mark J. de Lange,Maarten H. Vermeer,Anton W. Langerak,Pieter A. van der Velden	2016	16
5	Targeting of the MAPK and AKT pathways in conjunctival melanoma shows potential synergy Data Archiving and Networked Services (DANS) ·Robert M. Verdijk,Jingli Cao,Renier C. Heijkants,Aart G. Jochemsen,Mehmet Doğrusöz,Mark J. de Lange,Pieter A. van der Velden,Sjoerd H. van der Burg,Martine J. Jager	2016	2
6	Targeting of the MAPK and AKT pathways in conjunctival melanoma shows potential synergy Oncotarget ·Jinfeng Cao,Renier C. Heijkants,Aart G. Jochemsen,Mehmet Doğrusöz,Mark J. de Lange,Pieter A. van der Velden,Sjoerd H. van der Burg,Martine J. Jager,Robert M. Verdijk	2016	53
7	Digital PCR Validates 8q Dosage as Prognostic Tool in Uveal Melanoma PLoS ONE ·Mieke Versluis,Mark J. de Lange,Sake I. van Pelt,Claudia Ruivenkamp,Wilma G. M. Kroes,Jinfeng Cao,Martine J. Jager,Gré P.M. Luyten,Pieter A. van der Velden	2015	84
8	Distribution of GNAQ and GNA11 Mutation Signatures in Uveal Melanoma Points to a Light Dependent Mutation Mechanism PLoS ONE ·Mark J. de Lange,Lubna Razzaq,Mieke Versluis,Sven Verlinde,Mehmet Doğrusöz,Stefan Böhringer,Marina Marinkovic,Gregorius P. M. Luyten,R. J. W. De Keizer,Frank R. de Gruijl,Martine J. Jager,Pieter A. van der Velden	2015	34
9	Embryonic Zebrafish: Different Phenotypes after Injection of Human Uveal Melanoma Cells Ocular Oncology and Pathology ·Wietske van der Ent,Claudia Burrello,Mark J. de Lange,Pieter A. van der Velden,Aart G. Jochemsen,Martine J. Jager,B. Ewa Snaar‐Jagalska	2015	23
10	Heterogeneity revealed by integrated genomic analysis uncovers a molecular switch in malignant uveal melanoma Oncotarget ·Mark J. de Lange,Sake I. van Pelt,Mieke Versluis,Ekaterina S. Jordanova,Wilma G. M. Kroes,Claudia Ruivenkamp,Sjoerd H. van der Burg,Gregorius P. M. Luyten,Thorbald van Hall,Martine J. Jager,Pieter A. van der Velden	2015	40
11	Accelerated antioxidant bioavailability of OPC‐3^® bioflavonoids administered as isotonic solution Phytotherapy Research ·M R Cesarone,Maria Giovanni Grossi,A. Di Renzo,Silvia Errichi,Frank Schönlau,James L. Wilmer,Mark J. de Lange,Julian Blumenfeld	2009	3
12	Impact of Statistical Errors on Active Phased-Array Antenna Performance Mark J. de Lange	2007	5
13	Predicting Falls In Individuals with Parkinson Disease Journal of Neurologic Physical Therapy ·Leland E. Dibble,Mark J. de Lange	2006	141
14	Studies on American-type Mozzarella cheese showing abnormal gas formation. Sciences des Aliments ·Claude P. Champagne,Mark J. de Lange	1990	2

About Mark J. de Lange

Mark J. de Lange is a scholar working on Ophthalmology, Immunology and Physical Therapy, Sports Therapy and Rehabilitation, having authored 14 papers that have together received 476 indexed citations. Recurring topics across this work include Ocular Oncology and Treatments (8 papers), Retinal Development and Disorders (4 papers), Immunotherapy and Immune Responses (3 papers), Melanoma and MAPK Pathways (3 papers), melanin and skin pigmentation (2 papers), Cutaneous Melanoma Detection and Management (2 papers), interferon and immune responses (1 paper) and Phytochemicals and Antioxidant Activities (1 paper). The work is most often cited by research in Physical Therapy, Sports Therapy and Rehabilitation (119 citations), Ophthalmology (235 citations) and Psychiatry and Mental health (103 citations). Mark J. de Lange has collaborated with scholars based in Netherlands, United States and China. Frequent co-authors include Leland E. Dibble, Pieter A. van der Velden, Martine J. Jager, Mieke Versluis, Jinfeng Cao, Wilma G. M. Kroes, Sjoerd H. van der Burg, Claudia Ruivenkamp, Gré P.M. Luyten and Aart G. Jochemsen. Their work appears in journals such as PLoS ONE, Medicine and Oncotarget.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact